FDA Approves INJECTAFER — American Regent, Inc.

American Regent, Inc. has received FDA approval for Injectable Ferric Carboxymaltose (INJECTAFER), a treatment that could alleviate current supply constraints for intravenous iron infusions in the chronic kidney disease and iron deficiency anemia markets. With the new entrant, the pharmaceutical landscape for parenteral iron therapy is expected to evolve, fostering competition that may drive down costs and improve patient access.